MetLife Announces 2Q 2026 Results
METLIFE INC (MET) filed an SEC Form 8-K — Results of Operations and Financial Condition. Page 1 of 25 Exhibit 99.1 For Immediate Release | Global Communications | MetLife, Inc. MetLife Announces 2Q 2026 Results Strong business momentum continues under New Frontier strategy • Net income increased 1% 1 to $705 million , or $1.09 per share. • Adjusted earnings increased
How this was made
The 30-second read
Why it matters
The filing updates MetLife’s reported net income and adjusted earnings available to common shareholders, plus detailed expense and investment-income components that can affect valuation and near-term sentiment.
Market read
This is a primary earnings-related disclosure that can inform next-session trading, especially for investors tracking adjusted earnings drivers and volatility components.
What to watch
Traders may focus on investment portfolio results, derivative and market risk benefit remeasurement volatility, and any notable items details that are not fully shown in the provided excerpt.
MetLife reported $19,154 million of GAAP total revenues and $1,573 million of adjusted earnings available to common shareholders for the three months ended June 30, 2026.
GAAP total revenues and adjusted earnings available to common shareholders were higher than the June 30, 2025 quarter, while GAAP net income available to common shareholders was nearly unchanged year over year and below the March 31, 2026 quarter. Adjusted earnings available to common shareholders per diluted common share increased from the prior-year quarter and was slightly higher than the prior quarter.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenuesGAAP | $19.15B | – | – |
| PremiumsGAAP | $11.44B | – | – |
| Universal life and investment-type product policy feesGAAP | $1.37B | – | – |
| Net investment incomeGAAP | $6.70B | – | – |
| Other revenuesGAAP | $845M | – | – |
| Net investment gains (losses)GAAP | −$428M | – | – |
| Net derivative gains (losses)GAAP | −$772M | – | – |
| Policyholder benefits and claimsGAAP | $11.34B | – | – |
| Policyholder liability remeasurement (gains) lossesGAAP | $18M | – | – |
| Market risk benefit remeasurement (gains) lossesGAAP | −$270M | – | – |
| Interest credited to policyholder account balancesGAAP | $3.07B | – | – |
| Policyholder dividendsGAAP | $125M | – | – |
| Amortization of DAC, VOBA and negative VOBAGAAP | $588M | – | – |
| Interest expense on debtGAAP | $292M | – | – |
| Other expenses, net of capitalization of DACGAAP | $2.96B | – | – |
| Total expensesGAAP | $18.12B | – | – |
| Income (loss) before provision for income taxGAAP | $1.03B | – | – |
| Provision for income tax expense (benefit)GAAP | $256M | – | – |
| Net income (loss)GAAP | $779M | – | – |
| Net income (loss) attributable to MetLife, Inc.GAAP | $736M | – | – |
| Net income (loss) available to MetLife, Inc.'s common shareholdersGAAP | $705M | – | – |
| Net income (loss) available to MetLife, Inc.'s common shareholders per diluted common shareGAAP | $1.09 | – | – |
| Adjusted earnings available to common shareholdersnon-GAAP | $1.57B | – | – |
| Adjusted earnings available to common shareholders, excluding total notable itemsnon-GAAP | $1.57B | – | – |
| Adjusted earnings available to common shareholders per diluted common sharenon-GAAP | $2.43 | – | – |
| Adjusted earnings available to common shareholders, excluding total notable items, per diluted common sharenon-GAAP | $2.43 | – | – |
| Total notable itemsnon-GAAP | $— | – | – |
| Book value per common shareother | $38.59 | – | – |
| Adjusted book value per common sharenon-GAAP | $57.71 | – | – |
| Return on MetLife, Inc.'s common stockholders' equityGAAP | 11.5 % | – | – |
| Adjusted return on MetLife, Inc.'s adjusted common stockholders' equitynon-GAAP | 17.0 % | – | – |
| Weighted average common shares outstanding - dilutedother | 646.9M | – | – |
| Premiums, fees and other revenuesGAAP | $13.65B | – | – |
| Year-to-date total revenuesGAAP | $38.23B | – | – |
| Year-to-date net income (loss)GAAP | $1.94B | – | – |
| Year-to-date net income (loss) available to MetLife, Inc.'s common shareholdersGAAP | $1.84B | – | – |
| Year-to-date premiums, fees and other revenuesGAAP | $27.97B | – | – |
Capital returns
- Share repurchases: (8.7) million common shares during the three months ended June 30, 2026.
- Common shares outstanding, end of period: 637.8 million.
- MetLife Policyholder Trust Shares: 102.5 million.
What drove it
- Premiums were $11,435 million, universal life and investment-type product policy fees were $1,372 million, and net investment income was $6,702 million.
- Net investment gains (losses) were $(428) million and net derivative gains (losses) were $(772) million.
- Market risk benefit remeasurement (gains) losses were $(270) million.
- There were no total notable items in the June 30, 2026 quarter.
Concerns
- Net derivative gains (losses) were $(772) million, compared with $74 million in the March 31, 2026 quarter.
- Interest credited to policyholder account balances was $3,067 million, compared with $1,674 million in the March 31, 2026 quarter.
- GAAP net income (loss) available to MetLife, Inc.'s common shareholders was $705 million, compared with $1,140 million in the March 31, 2026 quarter.
- Return on MetLife, Inc.'s common stockholders' equity was 11.5 %, compared with 18.2 % in the March 31, 2026 quarter.
What to watch
- The direction of net investment gains (losses) and net derivative gains (losses).
- Interest credited to policyholder account balances, which was $3,067 million in the June 30, 2026 quarter.
- The gap between GAAP net income available to common shareholders of $705 million and adjusted earnings available to common shareholders of $1,573 million.
- Further reductions in common shares outstanding, which ended the period at 637.8 million.
Balance sheet and cash flow
- Book value per common share: $38.59.
- Adjusted book value per common share: $57.71.
- Interest expense on debt: $292 million.
Analysis
MetLife reported $19,154 million of GAAP total revenues for the three months ended June 30, 2026, compared with $17,340 million for the June 30, 2025 quarter and $19,074 million for the March 31, 2026 quarter. Premiums were $11,435 million, universal life and investment-type product policy fees were $1,372 million, net investment income was $6,702 million, and other revenues were $845 million. Year-to-date GAAP total revenues were $38,228 million, compared with $35,909 million for the year-to-date period ended June 30, 2025.
GAAP net income available to MetLife, Inc.'s common shareholders was $705 million, or $1.09 per diluted common share. This compared with $698 million, or $1.03 per diluted common share, in the June 30, 2025 quarter and $1,140 million, or $1.74 per diluted common share, in the March 31, 2026 quarter. The quarter included net investment gains (losses) of $(428) million and net derivative gains (losses) of $(772) million. Market risk benefit remeasurement (gains) losses were $(270) million.
Adjusted earnings available to common shareholders were $1,573 million, or $2.43 per diluted common share, compared with $1,362 million, or $2.02 per diluted common share, in the June 30, 2025 quarter. The adjusted earnings figure was $1,586 million in the March 31, 2026 quarter, while adjusted earnings per diluted common share were $2.42. MetLife reported no total notable items for the June 30, 2026 quarter. Adjusted return on adjusted common stockholders' equity was 17.0 %, and adjusted book value per common share was $57.71.
Expense trends warrant attention. Policyholder benefits and claims were $11,335 million, while interest credited to policyholder account balances was $3,067 million, compared with $1,674 million in the March 31, 2026 quarter. Total expenses were $18,119 million. Income before provision for income tax was $1,035 million, versus $1,507 million in the prior quarter, and return on common stockholders' equity was 11.5 %, versus 18.2 %.
Capital allocation reduced the share base during the quarter. MetLife reported share repurchases of (8.7) million common shares, ending common shares outstanding of 637.8 million, and weighted average diluted shares of 646.9 million. The filing excerpt contains no forward guidance, no management commentary, and no reported segment tables, so the reported data do not establish an outlook or provide segment-level demand and profitability detail.
Not in the filing
stated, not guessed- Forward guidance for revenue, expenses, tax rate, earnings, capital returns, or other metrics.
- Prior-release outlook required for comparison against prior guidance.
- Segment revenue, segment adjusted earnings, segment drivers, and segment comparisons. The table of contents references segment sections, but their data are not included in the provided filing text.
- GAAP operating income, gross margin, and operating margin.
- Cash and cash equivalents, total debt, and other balance-sheet totals. The table of contents references consolidated balance sheets, but the related data are not included in the provided filing text.
- Operating cash flow and free cash flow.
- Common-stock dividend declaration or payment.
- Named executive quotes or CFO commentary.
- Reported percentage year-over-year and quarter-over-quarter changes for the listed metrics.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
The document is MetLife’s SEC Form 8-K (Item 2.02) attaching a Q2 2026 financial supplement with GAAP statements and non-GAAP adjusted earnings reconciliations.
Ticker impact
MetLife filed an 8-K with its Q2 2026 financial supplement, including GAAP net income and adjusted earnings available to common shareholders.
Likely modest, with direction dependent on how adjusted earnings and key drivers compare to Street expectations.
This is a primary-source earnings-related filing (8-K Item 2.02) with detailed income statement and adjusted earnings bridge, but the excerpt does not include consensus comparisons or guidance changes.
Market effects
Updates insurer earnings and investment income dynamics, relevant for life insurer peers’ read-through on profitability drivers.
No explicit regional macro or regulatory shock described in the excerpt.
No explicit global event linkage beyond standard multi-region segment reporting.
Counterpoint
Without explicit guidance changes or standout notable items in the excerpt, the market may treat this as routine reporting rather than a catalyst.
Key entities
- companyMetLife, Inc.
Subject issuer filing the 8-K with Q2 2026 results and financial supplement.
- regulatory_filingSEC Form 8-K
Primary disclosure vehicle for results of operations and financial condition.
